Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells
Authors:
- Xun HuXHXun Hu
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 71 (5) , 584-595
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Schisandrin B—A novel inhibitor of P-glycoproteinBiochemical and Biophysical Research Communications, 2005
- Recent advances in understanding the cell death pathways activated by anticancer therapyCancer, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas StimulationJournal of Biological Chemistry, 2004
- Transcriptional regulators of the human multidrug resistance 1 gene: recent viewsBiochemical Pharmacology, 2002
- Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide SynthaseJournal of Biological Chemistry, 2001
- Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cellsBlood, 2000
- Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth ArrestJournal of Biological Chemistry, 1998
- Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cellsInternational Journal of Cancer, 1996
- Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cellsNature Medicine, 1996